












wMaterials Today  Volume 19, Number 2 March 2016 RESEARCH
Calcium phosphates in biomedical
applications: materials for the future?
Wouter Habraken1, Pamela Habibovic2, Matthias Epple3 and Marc Bohner4,*
1Max Planck Institute of Colloids and Interfaces, Department of Biomaterials, Am Mu¨hlenberg 1, 14476 Potsdam, Germany
2Maastricht University, MERLN Institute for Technology-Inspired Regenerative Medicine, Department of Instructive Biomaterials Engineering,
Universiteitssingel 40, 6229 ER Maastricht, The Netherlands
3University of Duisburg-Essen, Inorganic Chemistry and Center for Nanointegration Duisburg-Essen (CeNIDE), 45117 Essen, Germany
4 RMS Foundation, Bischmattstrasse 12, 2544 Bettlach, Switzerland
Our populations are aging. Some experts predict that 30% of hospital beds will soon be occupied by
osteoporosis patients. Statistics show that 20% of patients suffering from an osteoporotic hip fracture do
not survive the first year after surgery, all this showing that there is a tremendous need for better
therapies for diseased and damaged bone. Human bone consists for about 70% of calcium phosphate
(CaP) mineral, therefore CaPs are the materials of choice to repair damaged bone. To do this successfully,
the process of CaP biomineralization and the interaction of CaPs and biological environment in the body
need to be fully understood. First commercial CaP bone graft substitutes were launched 40 years ago, and
they are currently often regarded as ‘old biomaterials’ or even as an ‘obsolete’ research topic. Some even
talk about ‘stones’. The aim of this manuscript is to highlight the tremendous improvements achieved in
CaP materials research in the past 15 years, in particular in the field of biomineralization, as carrier for
gene or ion delivery, as biologically active agent, and as bone graft substitute. Besides an outstanding
biological performance, CaPs are easily and inexpensively produced, are safe, and can be relatively easily
certified for clinical use. As such, CaP materials have won their spurs, but they also offer a great promise
for the future.Introduction
Calcium phosphates (CaPs; Table 1) are the main constituents of
bone and teeth and play as such an essential role in our daily lives.
Following the logic that damaged tissue can best be repaired by
something with close resemblance, biomaterials based on CaPs were
already proposed for fracture treatment in 1920 [1]. CaP biomedical
research soared in the 1970s and CaPs were proposed for a broad
range of orthopedic and dental applications [2–6] (Table 2). These
materials varied from thin coatings on metallic implants to aid
implant fixation into bone [7] to sintered CaP to be used as synthetic
bone graft substitutes [8]. Truly impressive clinical successes have
been achieved with such materials, for example to increase the
clinical survival rate of the femoral component of total hip implants*Corresponding author:. Bohner, M. (marc.bohner@rms-foundation.ch)
1369-7021/ 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY
j.mattod.2015.10.008 [9], to reduce the risk of pin loosening for external fixators [10], or to
allow earlier weight bearing after tibia plateau fractures [11]. In some
cases, CaPs are even superior to autografts [12]. Nevertheless, all
these achievements have become somewhat overshadowed by the
advances in the field of polymers for biomedical applications that
seem endlessly diverse when it comes to control of composition and
related properties (e.g. co-polymers, supramolecular self-assem-
blies), applicable processing techniques (e.g. additive manufactur-
ing) and functionalization possibilities (e.g. surface micro-and
nanostructuring, chemical functionalization).
In the perspective of these recent developments in the field of
biomaterials, which have been underlined in a large number of
recent review articles (Table 3), the question arises whether CaPs
are old biomaterials, functional, but not particularly elegant? Or
do they stand the chance to become the materials of the future?-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). http://dx.doi.org/10.1016/
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TABLE 1
Main calcium orthophosphate compounds (taken from [143]). The first 6 compounds precipitate at room temperature in aqueous
systems. The last 6 compounds are obtained by thermal decomposition or thermal synthesis. The 6 columns contain the name, the
chemical formula, the Ca to P molar ratio, the mineral name, and the typical acronym, respectively. When x > 0 in the chemical
composition of ‘precipitated hydroxyapatite’, one talks also about ‘calcium-deficient hydroxyapatite’ (CDHA). Generally, x = 1 so that
CDHA has in most cases the composition Ca9(HPO4)(PO4)5OH.
Name Formula Ca/P Mineral Symbol
Monocalcium phosphate monohydrate Ca(H2PO4)2H2O 0.50 – MCPM
Dicalcium phosphate CaHPO4 1.00 Monetite DCPA
Dicalcium phosphate dihydrate CaHPO42H2O 1.00 Brushite DCPD
Octocalcium phosphate Ca8H2(PO4)65H2O 1.33 – OCP
Precipitated hydroxyapatitea Ca10x(HPO4)x(PO4)6x(OH)2x 1.33–1.67 – PHA
Precipitated amorphous calcium phosphate Mu(Ca3)(HPO4)3v(PO4)3yzH2O)b,c 0.67–1.50 – ACP
Monocalcium phosphate Ca(H2PO4)2 0.50 – MCP
a-Tricalcium phosphate a-Ca3(PO4)2 1.50 – a-TCP
b-Tricalcium phosphate b-Ca3(PO4)2 1.50 – b-TCP
Sintered hydroxyapatite Ca10(PO4)6(OH)2 1.67 Hydroxyapatite SHA
Oxyapatite Ca10(PO4)6O 1.67 – OXA
Tetracalcium phosphate Ca4(PO4)2O 2.00 Hilgenstockite TetCP
a x may vary between 0 and 2.
b u may vary between 0 and 3, v may vary between 0 and 1.5, y may vary between 0 and 0.667, and z is unclear at this point. M is typically a monovalent cation (Na+, K+, NH4
+) which is only
present if there is an overall negative charge on the calcium phosphate.
c ACP produced in basic conditions has generally u = 0, v = 0, y = 0.667, leading to the following composition: Ca3(PO4)2zH2O where z = 3–4.5. In acidic conditions, u = 3, v = 1.5, y = 0,











eviewUnlike the large majority of both natural and synthetic polymers
used in biomedical applications, CaPs are present in the human
body and are thus relatively easy to certify. This advantage should
not be underestimated at a time when the need for successful and
yet affordable strategies for the treatment of diseases and the
regeneration of malfunctioning organs and tissues is increasing
at a high rate, as a consequence of an aging population in the
Western world. CaPs meet these requirements; they can be pro-
duced in large quantities, against relatively low cost, they are
stable and therefore available off-the-shelf. Nevertheless, their
use is also associated with drawbacks, with poor mechanical
properties being probably the most relevant one for application
in orthopedics and dentistry. This, taken together, shows that
additional efforts need to be placed to further advance biomedical
strategies based on CaPs, but also that these materials deserve such
efforts.
In the current review, we aim to highlight important recent
developments in CaP research, divided into the topics biominer-
alization, nanoparticles for targeted delivery, and bone graft sub-
stitution. We also aim to provide an outlook toward the future of
CaPs in biomedical applications.
Biomineralization
Biomineralization can be described as a phenomenon in which a
mineral is integrated as a functional and often structural part of
living organisms, often in direct and close contact to a matrix
forming protein or carbohydrate structure. The superb properties
and intriguing complexity of most mineralized structures are
indeed a result of the interactions between organic molecules/
matrices and the mineral itself [13]. Examples of biominerals
found in nature are numerous as described in detail by Lowenstam
and Weiner [14]. Most common are the calcium carbonate-based
biominerals like aragonite (nacre) and calcite (mussels, exoskele-
tons of crayfish, etc.), CaPs (in vertebrate bone and teeth) and
silicates (plants, sea sponges) but also much rarer natural minerals70exist. A great number of studies have investigated mineral synthe-
sis under biologically relevant conditions, with the aim to explain
the mechanisms behind biological mineral. Crude simplifications
of the physicochemical conditions are a necessity in these studies
as the complexity of the real biological environment hampers
execution of mechanistic studies. In the next chapters, we will
focus on developments in the field of CaP biomineralization in
both biological and synthetic systems. Important discoveries in
the last decade have provided us a deeper understanding of the
mechanisms of biological and abiotic CaP mineralization, espe-
cially regarding the role of amorphous precursors and charged
organic molecules.
Bone mineral
The most prominent representative of CaP biomaterial is verte-
brate bone, an intricate composite of collagen, non-collagenous
proteins and mineral ordered in a distinct hierarchical fashion
[13,15,16]. Bone mineral, which is often referred to as biological
apatite or dahlite, is distinctly different from the geological apatite
mineral. First of all, bone mineral consists of nanometer-sized
platelets or needles [16], incorporated within collagen fibrils,
and oriented with the c-axis in the direction of the fibril [17].
Additionally, it does not have the hexagonal crystal morphology
of geological apatite and is also described as monoclinic apatite
[18,19]. Furthermore, bone mineral contains a number of ionic
substitutions such as CO3
2 in OH (A-substitution) and PO4
3
sites (B-substitution), or Na+, Sr2+ and Mg2+ in Ca2+ sites. In fact,
apatite is known for its ability to undergo ionic exchange with
metal ions in aqueous solutions [20,21], hence explaining the high
variability in bone mineral composition. Also, hydroxide, one of
the primary constituents of hydroxyapatite, has been reported to be
absent in bone mineral [22]. Finally, bone mineral is often de-
scribed as poorly crystalline, which probably relates to the small
size of the crystals as well as residual stresses in the crystal lattice.
While amorphous calcium phosphate (ACP), a likely precursor for
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TABLE 2
Short and non-exhaustive historical overview of important achievements in CaP research.
Year Discovery Reference
1920 Use of an aqueous slurry of ‘Triple Calcium Phosphate’a to stimulate bone growth [1]
1934 Use of tricalcium phosphate, MCP, and DCP slurries to stimulate bone growth [327]
1936 Polyphosphates discovered in yeast [328]
1965 Apatite precursor phase, Posner cluster [25]
1969 Synthesis of dense HA for prosthetic applications [329]
1970 Importance of macropores for bone regeneration [185,186]
1971 Implantation of ‘degradable’ tricalcium phosphate ceramic in rats [133]
1973 CaP-mediated transfection [119]
1975–1979 Clinical study with b-TCP and HA [3,330]
1975–1982 First commercial CaP products: ‘Synthograft/Synthos’ (b-TCP; 1975),
Ceros HA (HA, 1980), Durapatite (HA, <1981), ProOsteon (HA, 1981),
Calcitite (HA, 1982), Alveograf (HA, 1982), Ceros TCP (b-TCP, 1982), BioBase (a-TCP, 1982)
1976 Description of the hydraulic properties of a-TCP [331]
1980–1987 CaP Coatings [332,333]
1982–1987 CaP cements (CPCs) [137,334–336]
1985–1990 CaP used as carriers for drug delivery [337,338]
1985 Importance of micropores for bone regeneration [5]
1987–1999 Injectable/non-setting pastes (‘Putties’) [152,153,159,339]
1990–1991 Osteoinductivity [213,251]
1992–1999 Bone augmentation [340,341]
1994 Production of HA Whiskers by hydrothermal synthesis [342]
1994–1995 Clinical study with CPC, commercial launch of Norian SRS and BoneSource [138,343]
1997 Production of CaP scaffolds by rapid prototyping [188]
1999 Si-substituted HA [344]
2000 Polymer-induced liquid precursor (PILP) [345]
2001–2004 Biomimetic CaP scaffolds, macroporous CPC [175,346–349]
2002–2008 b-TCP synthesis by precipitation in hydrothermal conditions or in organic liquids [312,350,351]
2003 Micronization/amorphization by milling [352]
2003 Ready-to-use CPCs, dual-paste CPCs [144,147]
2003–2004 Custom-made CaP nanoparticle for gene delivery (transfection) [116,353,354]
2004–2006 Hydrated layer on apatite crystals [355,356]
2005 Flame-synthesized CaP nanoparticles [357]
2005–2013 Re-discovery of the importance of micropores for bone formation [202–205,358–362]
2005–2007 3D printing of CaP scaffolds [189–191,363]
2008 Nano-particulate apatite paste as bone substitute [151]
2008 New Ca–Mg phosphate phase diagram [364]
2008 ACP found in evolving bone [38]
2010–2011 Use of Ca and Phosphate ions as drugs (Bioinorganics) [132,273]
2010 Validation of the PILP model [58]
2012 Protein-free template mineralization [59]
2012 Covalent functionalization of CaP nanoparticles [109]
2013 Detailed description of ACP formation in vitro [23]
aMost likely an apatite powder with CDHA composition.
TABLE 3
List of selected reviews published after the year 2000 in the CaP
field.
Topic Reference
Calcium phosphates (general review) [27,365–368]
Biphasic calcium phosphates [369]
a-TCP, DCPA, DCPD, OCP, TetCP [370–373]





Sintering, scaffold production [375,390,391]
Osteoinductivity [263,392,393]
Drug/gene delivery [71,73,75,394–397]
Ionic substitution, ion exchange,
bioinorganics
[21,273,281,298,324,388,398]













wthe formation of bone mineral, has never been directly observed in
mature bone, there is often a significant substitution of PO4
3 by
HPO4
2 in the mature bone, which is a remainder of a transfor-
mation via ACP and octacalcium phosphate (OCP) precursors
during the precipitation around neutral pH [23]. Taking into
account all above, a complete description of bone mineral, accord-
ing to the current state of knowledge, would be the following: ‘a
poorly crystalline, highly substituted apatite consisting of very
small crystallites’ [24].
Amorphous calcium phosphate
While crystalline CaP compounds are most widely used in bio-
medical applications, ACP appears to be involved in the formation
of the majority of complex CaP structures. This hydrated, seem-
ingly unstructured, and often very unstable material is most likely
used as biological pathway for shaping and structuring bone71











eviewmineral. The first attempt to describe ACP was made by Eanes et al.
[25] who studied the mineralization of a highly concentrated CaP
solution with X-ray diffraction (XRD). These authors observed the
presence of two broad peaks in the XRD diffraction pattern of CaP
obtained at early time points. At longer maturation time, the CaP
eventually transformed into an apatite whose diffraction pattern
showed a remarkable resemblance to bone mineral. This observa-
tion led to the postulation of an ACP, consisting of 1.4 nm sized
‘Posner’s Clusters’ with a composition of Ca9(PO4)6. This model is
still commonly used to describe ACP with a Ca/P ratio of 1.5 in
experiments and calculation models, and is referred to as amor-
phous tricalcium phosphate (TCP) [26]. Recently, ACP was de-
scribed to be composed of Ca2(HPO4)3
2 clusters [23]. This
observation does not stand alone, as also earlier descriptions in
literature sometimes referred to a brushite-like chemistry of ACP
[27,28]. The protolysis equilibria of phosphate and the ability of
calcium to bind with both HPO4
2 and PO4
3 actually dictate that
the chemistry, and perhaps also short-range structural properties
of ACP change as a function of the pH, going from a PO4
3 rich
phase at high pH to a HPO4
2-rich phase at lower pH and physio-
logical conditions [29].
The amorphous precursor pathway: starting from pre-nucleation
species
Following the discovery of ACP, the formation of apatite in solu-
tion via an amorphous precursor was investigated in detail in the
1970–80s [30,31]. In all cases it reflected a cascade of events where
at first an amorphous precursor precipitated from the solution,
and then via multiple intermediate stages, often including a
second ACP-stage (referred to as ACPII) and OCP-stage (Ca8(H-
PO4)2(PO4)45H2O)), transformed into an apatitic CaP. As these
events occur rather fast, a correct analysis of this transformation is
tedious, especially when sample preparation affects the properties
of the analyzed material. Therefore, it is only recently that a
detailed chemical, morphological and structural description of
this system was given using cryo-TEM (Fig. 1) and various in situ
and ex situ techniques [23]. This study described a multistep-
process, starting from the aggregation of charged calcium-trihy-
drogenphosphate complexes (Ca(HPO4)3
4) in a dendritic-like
fashion in the prenucleation stage, which subsequently takes up
Ca2+/loses H+ to precipitate as the earlier described spheres of
acidic ACP (composed of Ca2(HPO4)3
2 post-nucleation clusters).
Accordingly, ribbons of a calcium-deficient OCP
(Ca6(HPO4)4(PO4)22) grow out of the ACP aggregates, a phase
that was originally described as ACP(II). These ribbons were ob-
served to be only 1.4 nm thick, thereby making them undetect-
able by XRD. The ribbons then transform into elongated plates of
OCP, which over a long period of time generate smaller platelets of
a calcium-deficient apatite. In this process, the calcium-triphos-
phate complex can still be found in the final apatite lattice but also
in the ACP and OCP-like intermediates.
ACP precursors in biological specimens: discovery and
transformation pathway
After the first description of ACP by Eanes et al. [25], and triggered
by the similarity of XRD patterns between bone mineral and
crystals forming from ACP in solution, it was proposed that a
similar mechanism of crystal formation occurs in bone as well.72However, all attempts to find ACP in (mature) bone remained
unsuccessful, which dictated the general opinion for decades to
follow [32]. Such evidence came only recently [33–38]. Initiated by
the work of Lowenstam and Weiner [14], spectroscopic and X-ray
evidence for the presence of a metastable amorphous precursor in
several calcium carbonate biomineral structures was obtained [39].
Based on this work, Mahamid et al. [36,38] and Beniash et al. [34]
detected the presence of an ACP in evolving zebrafish bone and in
newly formed murine enamel, the apatite structure specifically
found in teeth. Prerequisite for this observation was the careful
extraction and analysis of the specimens, which was done by state-
of-the-art techniques like X-ray absorption near edge structure
spectromicroscopy (XANES), Cryo-Scanning Electron Microscopy
and Synchrotron X-ray diffraction mapping. Moreover, Mahamid
et al. [36] were able to visualize the transformation pathway from
ACP to bone, showing cells with CaP-filled vesicles in the vicinity
of the newly formed bone which excrete the ACP particles that
subsequently attach to the non-mineralized bone matrix and
finally fuse to the mineralized matrix. A recent study by Akiva
et al. [33] indicated that the ACP particles are not necessarily
produced in the direct environment of the bone growth site,
but can also be supplied through blood. Studies on mouse calvaria
and long-bones [37] furthermore showed that bone related cells
like pre-osteoblasts, osteoblasts and osteocytes contain vesicles
that are filled with 80 nm-sized CaP granules, which consist of
even smaller particles, with a Ca/P ratio of 0.7. Although this Ca/P
ratio seemed to be deviating from the values described in literature
at that time point, and was different from the Ca/P ratio found on
the mineralizing zebrafish bone (Ca/P = 1.3), it corresponded well
with the one of acidic ACP, discovered afterwards [23]. Further-
more, evidence for an acidic ACP precursor in growing zebrafish
bone was recently obtained in a paper by Bennet et al. [35] by use of
in situ Raman and fluorescence imaging. Additionally, evidence
was obtained for an OCP(-like) intermediate (see also [33]), corre-
sponding to earlier work of Crane et al. [40] and the abiotic
mineralization mechanism [23].
All these results seem to contradict a direct mineralization from
the non-mineralized tissue by the surrounding serum. However, this
possibility cannot be completely excluded since the serum is super-
saturated with respect to apatite. Furthermore, the high amount of
mineralization inhibitors and promotors present inside the system,
which will be discussed in a following paragraph, makes it almost
impossible to predict whether a collagen matrix can be mineralized
in such an environment or not. Currently, the particle-excretion
mechanism seems to best explain the availability of high amount of
mineral that is required at the mineralization site.
Organic phosphates/polyphosphates
The observation of an amorphous orthophosphate precursor
seems to be in disagreement with the enzymatic degradation of
organic phosphates by alkaline phosphatase (ALP), necessary for
bone cells to produce a mineralized matrix in in vitro culture [41].
However, if the formation of ACP occurs within a vesicle, the
availability of phosphate indeed may be directed by the cleavage of
organic phosphate, slowly accumulating inside these vesicles.
Crystallization of the ACP could then be inhibited by control over
Ca2+ concentration and pH. An alternative explanation for the
presence of CaP inside vesicles is polyphosphate [24], a covalent
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FIGURE 1
Chronological visualization of calcium phosphate solution crystallization by Cryo-TEM: (a) dendritic aggregates of pre-nucleation complexes, (b) amorphous













wpolymer of (PO3)-repeating units, which does not crystallize into
apatite unless it is cleaved by ALP into orthophosphate. The Ca/P
ratio here can be similar to the 0.7 value measured for the vesicles
described above (Ca/P calcium polyphosphate = 0.5–1.0), further-
more, polyphosphate can be detected using DAPI-staining (which
then turns yellow [42]) and in situ Raman (only a very weak signal).
The presence of polyphosphate-filled vesicles has been observed in
marine bacteria and diatoms [43] where they act as a stable, yeteasily accessible storage of phosphate, which after enzymatic
degradation locally raises the levels of orthophosphate above
the nucleation limit. Lately, polyphosphate was also observed
to be a major source of inorganic phosphate for the slowly growing
tesserae of elasmobranches (sharks and rays) [44]. Although for the
growth of zebrafish bone the evidence points toward the role of an
acidic ACP [33,35], polyphosphate might play a similar role in
many other systems.73











eviewThe polymer-induced liquid precursor phase (PILP): the role of
additives
Many studies published in the last 15 years suggest that biology
uses additives like proteins, foreign ions and small organic mole-
cules to prevent or induce mineralization [45–47]. In the described
particle secretion mechanism, an additive is likely involved to
prevent the otherwise unstable amorphous particles from crystal-
lizing or dissolving during their transport to the site of interest.
However, increasing the viscosity of the surrounding solution,
thereby delaying dissolution, might lead to the same result, as
indicated by a study of Gal et al. [48]. To understand the influence
of additives like proteins on CaP formation and biomineralization,
numerous comparative studies have been performed. One of the
most important discoveries from these studies, originally de-
scribed for calcium carbonates, is the so-called polymer-induced
liquid precursor process (PILP process [46,49–51,345]). Here,
Gower et al. were able to stabilize a highly concentrated liquid-
like mineral precursor by negatively charged carboxylic acid-con-
taining polyelectrolytes like poly(aspartic acid) and poly(acrylic
acid) [49]. The systematic presence of charged residues which can
bind with Ca2+ or PO4
3/HPO4
2/CO3
2 (see also Schenk et al.
[52]) on a polymeric chain, was suggested to be the main cause for
the occurrence of this PILP state. Recent speculations on the
formation mechanism of amorphous calcium carbonate (ACC)
point toward a spinodal decomposition mechanism [53,54], that
is an instant decomposition of a highly concentrated solute into
an ion-rich and an ion-poor phase. The PILP could represent such a
spinodal decomposition on a local scale, where the necessary
increase in concentration is reached by the ion-attracting polymer
chains. However, the exact properties of the PILP-phase are not
clear yet [55], representing either a polymer-stabilized amorphous
phase or a stage before that. In any case, however, the PILP
represents an easily moldable, unstructured material, enabling a
fast and convenient mineralization process of complex matrices
[56]. Although originally met with skepticism as the analogy of a
charged polymer and a mineralization-controlling matrix protein
seemed too much of a shortcut, the highly charged amino acid
sequence of all known protein-based CaP inhibitors seems to
beckon that this phenomenon also occurs in biology [57]. A
validation of the PILP model for the mineralization of collagen
fibrils has been shown by Nudelman et al. [58]. By use of a
polyaspartic acid-stabilized CaP PILP, they were able to produce
oriented apatite platelets inside the collagen fibril as visualized by
cryo-TEM imaging and tomography, identical to those observed in
vertebrate bone. The postulated mechanism of mineralization
then involves the infiltration of the PILP into the collagen by
ionic interactions, where the collagen forms a template for the
formation of the apatite platelets. Also without the addition of a
negatively charged polymer, a bone-like mineralization of colla-
gen fibers was observed recently [59], questioning the necessity of
a PILP-like intermediate. The authors speculated that the specific
attractive interactions of collagen matrix alone might be enough
to initiate the formation of the typical bone mineral structure.
However, also here the highly concentrated SBF solution likely led
to the formation of an amorphous intermediate phase, which is
stabilized by impurities like foreign ions (SO4
2, CO3
2, Mg2+) [60]
present in SBF. The templating action of the collagen therefore
seems to be important, however, only when in the presence of a74stabilized amorphous/PILP phase, as most attempts to mineralize
collagen by a CaP solely led to peripheral deposition of mineral. In
a recent paper of Pompe et al. [61], the templating action of the
collagen is described to be a result of the coherent evolution of
tropocollagen and OCP. This process is enabled by the interaction
of units of post-nucleation complexes inside the OCP and its
precursors [23] and amino-acid triplets within the tropocollagen,
which show a perfect structural fit. It indicates that the structure of
collagen can be interpreted as being the result of a ‘survival of the
fittest’ in the formation of CaP-based biocomposites in living
organisms.
The efficiency of additives to stabilize an amorphous or PILP
stage is largely dependent on their nature. For example, in contrast
to most foreign ions, crystallization of the ACP is significantly
delayed by adding only a small amount of (poly)-glutamate or
polyphosphate [60]. In fact, many examples in biology indicate
that ACP-stabilizing agents are highly phosphorylated [45,62–64].
A classical example, although beyond the scope of biomineraliza-
tion, is casein micelles, phosphoprotein–CaP complexes [62,65]
that are found in milk. Thanks to the formation of these micelles,
the level of calcium present in milk is raised without causing
precipitation. Additionally, it is suggested that this complexation
improves the intestinal resorption of Ca2+, and evidence is given
for the remineralization of enamel caries by human and animal
studies [62]. The CaP inside these micelles is X-ray amorphous, and
especially the phosphorylated seryl-cluster motif inside the casein
is responsible for the interaction with the CaP [62], although the
overall charge of the protein also has an effect. This system is
therefore clearly in accordance with the PILP-model, where only
the complex between the organic and the inorganic material is
able to execute its biological function. Another example is fetuin-
A, a liver-derived blood protein, which is an important inhibitor of
ectopic calcification as shown in a study in knock-out mice [47]. In
biological samples, fetuin-A/CaP complexes are observed as elon-
gated 200 nm-long crystalline colloidal structures [64]. Although
phosphorylated residues are also present here, a comparative study
has shown that the binding behavior between the fetuin-A and
CaP is lost upon blocking the carboxylic acid residues, and the
inhibitory effect is mostly regulated by the cystatin-like Domain
D1 [66]. In contract to the casein, phosphorylation might aid
mineralization here, but is not necessary to control it. Another
system which has been studied in great detail is the formation of
dental enamel and the role of amelogenin [34,45,67,68]. Here,
Cryo-TEM analysis and structural analysis of the protein have
demonstrated a templating interaction between the forming min-
eral and amelogenin [67,68]. As expected, phosphorylation of the
amelogenin seems to be beneficial for the stabilization of ACP,
although it is not a prerequisite for the formation of enamel-like
structures in mineralization reactions [45]. The ternary structure of
the amelogenin seems to be important in the templating interac-
tion, and is influenced by the presence of phosphorylation groups
[45]. A similar templating interaction where the protein undergoes
structural deformations upon binding with the CaP was also
observed with the dentin matrix-protein-1 [69], a phosphorylated
protein involved in dentin formation, and with osteopontin [63], a
highly phosphorylated glycoprotein which is expressed in many
mineralized and soft tissues. Finally, a well-known example of a
phosphorylated molecule that stabilizes ACP is DNA, forming













wnanometer-sized DNA–CaP complexes [70], which are used for cell
transfection (see below), although little is known about the actual
stabilization mechanism. Overall, phosphorylation seems to be
important for the stabilization of ACP to achieve a possible tem-
plating interaction between the protein and the CaP and to
influence the ternary structure of the protein. It is plausible that
most of these functions can also be achieved by carboxylic acid
residues, although chemical similarity between the phosphorylat-
ed residue and the CaP could be an important advantage.
Calcium phosphate nanoparticles and gene delivery
While understanding the fundamentals behind biomineralization
will undoubtedly lead to new ideas for design of CaPs in the
biomedical field, impressive results have already been achieved
in a variety of applications. One such application is targeted drug
delivery using CaP nanoparticles. CaP nanoparticles can be syn-
thetically prepared and used for the delivery of (bio)molecules in
the body and also into cells [71–75]. A clear advantage compared to
other nanoparticles is their high similarity to bone mineral as
stated above, making them biocompatible, and also their biode-
gradability under moderately acidic conditions (like during the
resorption by osteoclasts or inside a cell in a lysosome) [76]. In
addition, CaP is well known as excellent adsorbent for many
biomolecules, a property that has led to its application in the
chromatographic separation of biomolecules like nucleic acids
[77]. As other nanoparticles, CaP nanoparticles are taken up by
cells by endocytosis and related mechanisms [78–83]. They end up
in endosomes which subsequently fuse with lysosomes with an
acidic pH (around 4). Under these conditions, CaP dissolves [84].
The corresponding ions can be metabolized or excreted by the cell.
Whereas phosphate is harmless, an increased level of calcium ions
in the cytosol can be harmful and may lead to subsequent cell
death [85,86]. Unless the cell is able to pump out the calcium ions
within a few hours, it will eventually die. This happens if cells are
subjected to large quantities of CaP nanoparticles, an effect which
is also discussed in the context of atherosclerosis [87].
However, if moderate amounts of CaP nanoparticles are applied,
they are well tolerated [88], and the nanoparticles can serve as
carriers to transport all kinds of molecules across the cell mem-
brane [89,90]. It is important to note that many molecules cannot
cross the cell membrane alone due to their charge or their size, and
that many receptors for drug molecules are located inside the cell
[91]. In the following, we will discuss current applications of
functionalized CaP nanoparticles.
A prerequisite for a successful application of nanoparticles is
their colloidal stability in the dispersion medium. This medium is
often water after the synthesis, but in the cell culture and in the
body it consists of an aqueous solution of salts, carbohydrates,
lipids, and proteins [92–95]. While an increasing salt concentra-
tion often leads to the destruction of an electrostatic colloidal
stabilization and subsequent agglomeration, the adsorption of
proteins can enhance the dispersibility due to an additional steric
stabilization. If the nanoparticles are not sufficiently colloidally
stabilized, they will agglomerate to microparticulate aggregates
which will not be able to penetrate the cell wall due to their size,
and which will be rapidly degraded by phagocytosis [96].
Prominent biomolecules which alone cannot penetrate the cell
wall due to their negative charge are nucleic acids, that is DNA,RNA and other oligonucleotides. With the help of nanoparticles,
they are able to enter cells and influence the protein synthesis
inside a cell [97–99]. The non-viral introduction of DNA into
a living cell is called transfection. If the DNA travels into the
cell nucleus, it will cause the production of the protein whose
sequence is encoded in the DNA. This is a way to specifically
upregulate the protein synthesis inside a cell. The other option is
the introduction of small-interfering RNA (siRNA) or micro-RNA
(mRNA) into a cell which can suppress the production of a specific
protein (‘gene silencing’) already by their presence in the cytosol.
Together, these two techniques can be used to genetically
manipulate cells and tissues and to enhance or suppress
specific proteins, constituting the exciting field of ‘gene therapy’
[97–100].
Cells take up nanoparticles as long as they have a suitable size
(up to about 200 nm) and charge (a positive charge helps), regard-
less of their chemical composition [78,79,81]. Obviously, this
creates problems when a specific tissue is to be addressed by
nanoparticles. To address tumors, the so-called ‘enhanced perme-
ation and retention effect’ (EPR effect) is often proposed [96,101].
In this process, the facts that the blood vessels leading to a tumor
are leaky (i.e. possess larger pores than normal blood vessels) and
that a tumor does not possess a lymphatic system lead to an
enrichment of nanoparticles inside a tumor. Broadly speaking,
the access of nanoparticles to a tumor is enhanced and their
removal is restricted, causing an enrichment of nanoparticles
inside the tumor. A second option is the surface-functionalization
of nanoparticles with suitable targeting moieties like antibodies,
peptides or aptamers to direct them to a specific cell or tissue type
[102–106]. This can be easily achieved for metallic nanoparticles
(e.g. gold, silver) by thiol coupling chemistry [107,108], but does
not work straightforward for ionic CaP where a direct covalent
functionalization is impossible. However, after the addition of a
coating layer of silica, CaP can be easily functionalized by well-
established siloxane chemistry [109].
Gene therapy in biomaterials science typically involves the
upregulation of genes which enhance bone or vessel growth. This
leads to the production of proteins like bone morphogenetic
proteins (BMPs) or vascular endothelial growth factor (VEGF)
[110,111]. With DNA being cheaper and easier to prepare and
purify than proteins, this is a promising alternative to conven-
tional delivery of the proteins, for example into an implantation
site or a bone defect. Conceptually, the protein level is also more
constant due to the permanent production by the surrounding
cells. As the transfection with nanoparticles is only temporary (a
couple of days or weeks), there is no risk of a permanent genetic
manipulation of the host.
Besides other types of nanoparticles and polymers, custom-
made CaP nanoparticles have attracted attention as biocompati-
ble, inorganic gene delivery systems [75,112–116]. Different ways
to achieve a local transfection have been proposed, ranging from
an electrophoretic deposition of DNA-loaded nanoparticles on
metal surfaces [66] to their incorporation into polymer films in
a layer-by-layer process [117] to a water-based paste of CaP nano-
particles for direct introduction into a bone defect (Fig. 2) [118]. It
should be noted that in situ precipitated CaP nanocrystals have
been used as transfection agent in cell biology since 1973 [119],
albeit with limited reproducibility and efficiency [120,121].75
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FIGURE 2
Calcium phosphate nanorods, loaded with DNA encoding for BMP-7 and











eviewCaP nanoparticles can be visualized in cell cultures and in vivo
by adding suitable fluorescent moieties. One way is the incorpo-
ration of fluorescent lanthanide ions like Eu3+ into the CaP lattice
[122–124]. The other way is the functionalization (either covalent
or by adsorption) with fluorescent dyes [84]. This permits an easy
detection of nanoparticles inside cells and also in vivo when near-
infrared dyes (NIR) are used [125].
In principle, CaP nanoparticles can be loaded with almost all
molecules and drugs, except for hydrophilic small molecules which
will be washed out by the surrounding aqueous medium. If they are
prepared in a multi-shell way, they can carry more than one drug or
fluorophore (Fig. 3). Their applicability in immunology has also been
demonstrated, together with other kinds of nanoparticles [126].
They were loaded with TLR ligands to stimulate an immune response
and with specific antigens against viral infections. It was shown both
in vitro and in vivo that such CaP nanoparticles can upregulate the
immune response and lead to both prophylactic and therapeutic
vaccination [127], also against retroviruses [128]. Remarkably, it has
been shown that CaP nanoparticles alone can enhance the immune
response, even without biomolecules [129,130].FIGURE 3
A multi-shell calcium phosphate nanoparticle, carrying an antigen and a
TLR ligand as adjuvant for stimulation of the immune system [401].
76In summary, CaP nanoparticles represent a promising alterna-
tive to other nanoparticles (e.g. gold, silica, polymers) because the
body is already accustomed to them, because they dissolve after
cellular uptake, and because they can be loaded with many differ-
ent (bio-)molecules. Their synthesis is comparatively easy,
straightforward and inexpensive.
Calcium phosphate bone graft substitutes
CaPs are among the best bone graft substitutes because they
promote rapid bone formation on their surface, and may assure
bone healing within a year. Several reasons can be invoked to
explain these excellent properties: (i) the main constituent of our
bone is biological apatite (as demonstrated above), therefore cal-
cium and phosphate ions are present in large quantities in human
body; (ii) various CaPs are resorbed by a cell-mediated process
[5,131], ensuring not only a concomitant material resorption and
bone formation process, but also an absence of biocompatibility
issues due to the uncontrolled release of large amounts of degra-
dation products; (iii) calcium and phosphate ions have a direct
potent effects on bone cells, with in particular phosphate ions
being thought to trigger an osteoinductive response [132].
CaPs were first proposed as bone graft substitute in the 1970s
[2,133], but it was only in the late 1990s that their use spread out as a
consequence of the appearance of diseases such as AIDS [134], and
BSE [135], as well as stricter regulation for nature-derived products
(xeno- and allografts). Even though the basics of the use of CaP
materials for bone substitution were laid early on, important
improvements have been achieved in the last decade: design of
ready-to-use injectable pastes, much better understanding of the
factors triggering the osteoinductivity of CaP bone graft substitutes,
or development of additive manufacturing approaches allowing the
production of custom-made implants in the operating room.
Handling of CaP bone graft substitutes
Originally, CaP bone substitutes were only available as sintered
blocks and granules [4,133]. Porous blocks (pre-forms) excel in
filling of defects with a predictable shape and size, such as burr
holes, osteotomy gaps, and cavities in inter-body fusion cages, but
tight filling of irregular defects with good implant-to-bone contact is
almost impossible. Contrarily, granules can fill any defect form but
their handling is poor. Indeed, filling a narrow defect with granules
is very difficult, and if granules fall outside the borders of the defect,
they need to be removed, which may be cumbersome. Cleaner
application is facilitated by matching the granule size to the defect
size. As a result, granules are smaller in the dental field (<1 mm),
where bone defects are relatively small, than in the orthopedic field
(1–6 mm) [136]. Also, large efforts have been made over the past 4
decades to improve the handling of CaP bone graft substitutes with
the aim to provide injectable, moldable, and/or ready-to-use pastes.
Injectable CaP cements
In 1983, Brown and Chow [137] presented a CaP hydraulic cement
consisting of two CaP powders (tetracalcium phosphate and dical-
cium phosphate) and an aqueous solution. Hardening occurred
within less than an hour by a combination of raw material dissolu-
tion and apatite precipitation (i.e. crystallization). This discovery
opened up the possibility to provide injectable pastes to clinicians.
In 1995, a report on one of the first clinical uses of CaP cements













wsuggested that CaP cements could not only heal bone, but even
stabilize bone fractures, thus rendering the use of metallic internal
fixators, the so-called osteosynthesis plates and screws, obsolete
[138]. However, it soon appeared that internal fixators were still
needed because of limited mechanical properties of CaP cements,
and that the mixing system of the cement was difficult to use and
prone to errors. Also, not all of the paste could be extruded with the
injection system due to the so-called filter-pressing phenomenon:
the liquid migrating between the solid CaP particles while injecting
the paste, eventually leading to a wet densified powder plug at the
plunger side, unamendable to injection [139]. This problem was
solved in more recent CaP cement formulations by increasing the
viscosity of the mixing liquid [140–143]. Nevertheless, this ap-
proach is costly and CaP cement mixing still requires a large number
of manual operations before an injection can be performed. Also,
once the CaP cement is mixed, there is only a limited period of time
during which the cement can be injected.
Ready-to-use CaP cements and pastes
The very limited handling and injection window of CaP cements has
triggered the development of ready-to-use CaP cements consisting of
one or two pastes. One approach consists in keeping the cement
components in a non-aqueous hydrophilic or hydrophobic liquid
[144–146]. This approach works with any formulation, and harden-
ing only occurs once the paste is injected into the bone defect. On the
negative side, the use of an additional component makes production
and certification more difficult, and the release of large amounts of a
foreign liquid during injection may result in adverse biological
reactions. Also, hardening is slow and volume-dependent because
it relies on the exchange or replacement of water with the hydro-
philic or hydrophobic liquid [146]. A second approach to formulate
ready-to-use pastes consists in dispersing the reactive CaP powders in
aqueous solutions. Unfortunately, there are only very few reactive
CaP powders that can be stabilized in aqueous conditions. Lemaitre
et al. [147] proposed to combine an acidic (reactive) monocalcium
phosphate monohydrate (MCPM) paste with a basic (fairly inert) b-
tricalcium phosphate (b-TCP) paste to obtain brushite after reaction.
Recently, Bohner et al. [148] showed that small amounts of divalent
cations, such as Mg2+ can stabilize a-TCP aqueous pastes for at least
one year at room temperature, and that the latter paste can then be
reactivated by adding a small volume of highly concentrated Ca2+
solution. To minimize the drawbacks of the non-aqueous and aque-
ous approaches, Chow and Takagi [149] placed the reactive CaP
components in a non-aqueous paste and triggered the reaction by
mixing the non-aqueous pastes with an aqueous paste. Currently,
there are only very few commercial formulations due to issues such as
shelf-life stability [150], limited reactivity [148], sterilization, price,
and phase separation during storage, but there is a clear trend and
clinical desire toward ready-to-use CaP cements.
The difficulties to design ready-to-use CaP cements have led to
the development of non-hardening, ready-to-use pastes made of a
mixture of CaP particles and an aqueous solution [151–154]. Such
formulations are not only very easy to use (‘open the package and
inject’), but cheaper and easier to produce than CaP cements.
Nevertheless, there are concerns about the biological response of
dispersed CaP particles. Indeed, Malard et al. [152] described
inflammatory reactions after implanting 10–20 mm biphasic calci-
um phosphate (BCP, consisting of HA and TCP) particles. Similarresults were reported with sintered CaP particles [155] and CaP
cements [156]. Wang et al. also reported a loss of osteoinductive
potential with particles smaller than 45 mm [157]. However, what
is true for microparticles might not be true for nanoparticles,
because nanoparticular pastes have a much better cohesion than
microparticular pastes [158] and because nanoparticles – contrary
to microparticles – are much smaller than cells.
Moldable CaP pastes
Another trend of the new millennium is to combine the good
handling properties of a paste with the good biological properties
of a granular bone substitute. For that purpose, CaP granules are
embedded in a viscous polymer matrix which can be rapidly cleared
from the body by enzymatic cleavage or transport once implanted
[154,159]. A wide range of polymers has been considered, including
fibrin [160], hyaluronan [161,162], collagen [163,164], alginate
[159], various kinds of cellulose [153,165,166], and poly(trimethy-
lene carbonate) [167]. Generally, these pastes contain particles
larger than 50–100 mm, and may require to be mixed in the operat-
ing room. In the latter case, it is sometimes possible to produce or
combine the pastes with blood, bone marrow, or platelet-rich
plasma. In contrast to the previously mentioned problem of gran-
ules spreading around the defect site, the polymer provides cohe-
sion and keeps the particles in place until the wound is closed and
clotting occurs.
To conclude this section on the handling properties of CaP bone
graft substitutes, it is likely that ready-to-use pastes will soon
replace granules as the most frequently used form of CaP bone
graft substitute.
Calcium phosphates and bone healing
Historically, first efforts to synthesize and design CaP bone graft
substitutes were focused on sintered CaPs, namely sintered HA [3],
b-TCP [2,133], or their mixtures (BCP) [154,168]. The aim was to
obtain a material with sufficient mechanical strength for load-
bearing applications, in particular for internal fixation (‘osteo-
synthesis’), but still resorbable enough to allow a full conversion
into bone during bone regeneration. A special interest was paid to
sintered HA due to its crystallographic and compositional similar-
ity to bone mineral, its high strength, and its comparatively easy
production. However, whereas bone mineral can be remodeled by
the action of osteoclasts, sintered HA is biologically practically
inert and not biodegradable [169]. Furthermore, dense CaPs are
too brittle to be used in load-bearing applications, and polymer–
CaP composites have failed due to insufficient mechanical prop-
erties [170] or inadequate resorption behavior [171]. Therefore, a
paradigm shift occurred at the turn of the millennium: instead of
designing load-bearing bone graft substitutes, researchers aimed
for CaP bone graft substitutes providing a fast healing response,
that is a fast turnover from a bone defect to mature (= mechanically
competent) bone. Strategies have included a change in composi-
tion, and an improvement of the material architecture at both the
micro and macro level, as discussed in the following sections.
Change of composition to achieve faster bone defect
healing
Besides sintered HA and b-TCP, two other Ca orthophosphate
phases can be obtained by sintering: tetracalcium phosphate77











eview(TetCP) and a-TCP. Due to its basicity, TetCP has only been
proposed as antimicrobial agent [172]. Therefore, early efforts to
find a CaP material with fast resorption were focused on a-TCP, a
metastable polymorphic form of b-TCP that has a higher solubility
than b-TCP. CaP cements made of a-TCP powder are considered to
have excellent biocompatibility [138,173], not just after hydration
to CDHA, but also immediately after injection when the ceramic is
still mostly constituted of a-TCP. Also, the few studies reporting
the in vivo performance of implanted a-TCP granules are generally
positive [174]. Nevertheless, a-TCP is thought to be resorbed too
fast and has hardly been investigated as raw material for larger
granules and shaped blocks. So, until the discovery of CaP
cements, research remained focused on HA, b-TCP and their
mixtures (BCP).
The discovery of CaP cements widened the research scope by
allowing the synthesis of solids consisting of phases only stable
at or close to room temperature. Of particular interest are not
only the two typical end-products of CaP cement reactions,
namely calcium-deficient HA (‘CDHA’) [175,176], and dical-
cium phosphate dihydrate (DCPD; ‘brushite’), but also OCP
and dicalcium phosphate anhydrate (DCPA, ‘monetite’) [177–
180], which can be obtained by hydrolysis or dehydration of
DCPD. Apart from having often a higher solubility than that of
b-TCP, CaP materials produced at or close to room temperature
have two interesting features compared to sintered CaPs. First,
they have specific surface areas (SSA) that are often close to the
values of bone mineral (80 m2/g) and as such up to two orders
of magnitude higher than the values exhibited by sintered CaPs
(typically below 1 m2/g). High SSA values are believed to stimu-
late protein adsorption, which is a very important event in the
healing cascade. Second, DCPD and OCP are precursor phases for
apatite formation. Since bone mineral is also formed from pre-
cursor phases, as is described in the section on biomineralization
above, several authors have speculated that the in vivo conver-
sion of DCPD and OCP into apatite enhances bone formation
[181,182]. Indeed, DCPD [173,183] and OCP [181] are rapidly
converted to apatite after implantation. Also, DCPA, DCPD,
OCP, and CDHA have been suggested to have superior biological
properties compared to sintered CaP ceramics [184]. Neverthe-
less, the number of studies comparing sintered and non-sintered
CaP bone graft substitutes is very limited and their interpreta-
tion is constrained by the difficulty to control all physicochem-
ical properties of CaP materials affecting their biological
response. To date, it is possible to produce almost any type of
CaP in almost any shape, but studies proving the superior
biological behavior of CaP phases obtained at or close to room
temperature are still missing.
Architecture
n 1970, at the start of bone substitution research, Hulbert et al.
[185,186] already described the importance of pore and pore inter-
connection size for the biological response to porous ceramic bone
substitute. He recommended to incorporate pores larger than
100 mm (=macropores) into bone graft substitutes. In 1984, Klein
et al. [5] underlined the fact that not only macropores but also
micropores (typically close to 0.1–10 mm) were essential to provide a
fast resorption. However, it was only after the establishment of
tissue engineering by Langer and Vacanti in 1993 [187] that a boom78occurred in the research devoted to the control of the architecture of
CaP bone graft substitutes and to the understanding of the link
between implant architecture and biological response.
The first efforts to perfectly control the architecture of CaP bone
graft substitutes relied on stereolithography: polymer molds were
first printed and subsequently used for HA slip casting and sinter-
ing [188]. In 2005, Seitz et al. [189] started to directly print 3D
scaffolds using an ink-jet printer, a water-soluble polymer ink, and
HA powder. In 2007, Gbureck et al. [179,190,191] removed the
need to sinter the printed pieces by jetting phosphoric acid onto
an a-TCP powder to directly form a ready-to-use 3D printed
brushite scaffold without organic additives. Since several inks
can be used simultaneously, chemically complex scaffolds can
be produced, for example printed pieces with spatially localized
drugs [190]. Unfortunately, 3D printing is manually demanding
and printing hollow structures is strongly limited by the need to
remove the powder from unprinted volumes (the so-called
‘depowdering’; Fig. 4a) [192]. Also, it is not easy to perfectly
control the composition of the printed pieces, and post-treatments
in acids are generally required.
Another additive manufacturing technique called ‘robocasting’
is based on the extrusion of a thick (solid-rich) CaP slurry through
a thin nozzle [193] (Fig. 4b). Compared to 3D printing, robocasting
is not as versatile in terms of materials and geometries (not possible
to print overhanging parts) but provides a higher printing accura-
cy (typically below 100 mm [193] compared to 500 mm with 3D
printing [194,195]), and is not subject to the strong limitations of
the depowdering step encountered in 3D printing [192]. Initially,
robocast scaffolds relied on a two-step process consisting of (i)
printing, and (ii) sintering [193], but in the meantime, various
companies have developed CaP pastes that can be directly used to
print a scaffold in the operating room. Several companies have
started commercializing products based on additive manufactur-
ing, for example scaffolds with an oriented architecture to pro-
mote bone ingrowth in a specific direction [196], or innovative
craniofacial implants combining a 3D-printed titanium mesh and
DCPA ceramic tiles (Fig. 4c).
Considering that 60–70% of all bone graft substitutes are still
sold as granular materials, various research groups started working
on granules with controlled geometry, the goal being to control
the pore size created between the granules [197,198]. A particularly
interesting approach was proposed by Choi et al. [199] who used
injection molding to produce ‘tetrapods’. Nevertheless, despite all
efforts that have been made to produce CaP bone graft substitutes
with controlled architecture, the ideal architecture providing an
optimal biological response has been defined only in very general
terms [200] and is still a matter of debate [201–205]. Indeed, most
researchers will agree that micropores (around 1–10 mm) and
macropores (>100 mm) have a favorable effect on bone formation,
but precise recommendations regarding the pore volume fraction
or size are still missing.
Osteoinductive calcium phosphate ceramics and the use of
bioinorganics
One of the important achievements in the field of CaPs in the past
few decades was the development of materials with intrinsic
osteoinductivity. The importance of the phenomenon of osteoin-
duction, initially defined by Friedenstein as the process of the
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FIGURE 4
Examples of structures obtained by additive manufacturing techniques. (a) 3D printed scaffolds made of DCPA/monetite (scale bar: 5 mm) [192], (b) solid
obtained by robocasting (scale bar: 2 mm; courtesy of S. Heinemann, InnoTERE GmbH, Germany), (c) ‘Craniomosaic’: a DCPA based implant for treatment of
cranial bone defects. The device uses a 3D-printed titanium mesh covered with DCPA ceramic tiles (courtesy of J. Aberg, OssDsign, Sweden), (d) pattern of













w‘induction of undifferentiated inducible osteoprogenitor cells that
are not yet committed to the osteogenic lineage to form osteo-
progenitor cells’ [206] was recognized following the seminal work
by Urist, who showed bone formation by hydrochloric acid-dec-
alcified diaphyseal bone in muscles of rabbits, rats, mice and
guinea pigs [207]. Further work, directed toward understanding
of the mechanism of this heterotopic bone formation, led to
identification of Bone Morphogenetic Proteins (BMPs) as inducer
of the cascade of chemotaxis, mitosis, differentiation, callus for-
mation and finally bone formation [208]. In general, a successful
clinical application of BMPs, with emphasis on commercially
available BMP-2 and BMP-7 (OP-1) in spinal fusion and defect
caused by trauma [209–211], logically strengthened the perception
of osteoinduction as being a highly important property of a bone
graft substitute. First reports on heterotopic bone formation trig-
gered by a synthetic biomaterial that did not contain BMPs or any
other biological factors caused both disbelief and excitement,considering important advantages of synthetics versus biologics,
such as generally lower cost of production and better stability.
One of the first reports on de novo bone formation induced
heterotopically by a synthetic biomaterial was published in 1969,
where Winter and Simpson described an observation of bone
induction by a sponge made of polyhydroxyethylmethacrylate
(poly-HEMA) in the soft tissue of pigs [212]. It was, however,
not until 1990s that researchers actively started searching for
synthetic biomaterials with intrinsic osteoinductive potential.
Until now, a range of CaP-based biomaterials and a handful of
other materials, all with the ability to mineralize in vitro and in vivo,
have been shown to induce heterotopic bone formation to various
extents. Osteoinduction has been demonstrated for various CaP
phases, including HA [213–228], TCP [223,225,229–238], various
blends of the two in the form of BCP [218,219,221–225,236,
238–247], DCPD [179], DCPA [179], carbonated apatite (CA)
[239,240,248] and OCP [249,250], and in various forms such as
sintered ceramics [213,214,216,225,227,251,252], cements79











eview[179,224,247], coatings [249,250], as well as coral-derived ceramics
[213,214,227,228,253,254], in a number of animal models.
While a growing number of studies confirmed that osteoinduc-
tivity can be an intrinsic property of some CaP ceramics, the
clinically relevant question remained whether such ceramics
would also result in an improved regeneration of challenging,
critical-sized bone defects. In other words, can we consider
osteoinductive CaP as a true alternative to natural bone grafts?
In a number of studies, a direct comparison was made between
osteoinductive and non-osteoinductive ceramics in regenerating
bone defects, including critical-sized ones, in general concluding
that a more pronounced bone formation occurred with ceramics
with an osteoinductive capacity [179,239,241,248,255,256]. Al-
though in some of these studies an attempt was made, either by
implant design [179] or by analysis method [241], to prove that
osteoinduction, independent of osteoconduction, occurs in large
bone defects as well, no conclusive evidence has been presented
yet. Probably the best proof for clinical relevance of CaP ceramics
with intrinsic osteoinductivity was given in the study by Yuan
et al. in which an osteoinductive TCP ceramic was compared to an
autograft and to a rhBMP-2 construct [238]. The osteoinductive
ceramic was shown to be at least as successful in bridging an ovine
critical-sized iliac wing defect by newly formed bone as either the
autograft or the rhBMP-2 construct.
Despite these clinically relevant achievements, the mechanisms
behind the CaP-induced bone formation are still incompletely
understood. The facts that ceramic-induced bone formation is
always intramembranous, in contrast to BMP-2-induced forma-
tion that mainly occurs via the endochondral pathway [257], and
that material-induced ectopic bone formation is relatively slow as
compared to the BMP-2-driven case [218,235,258,259], suggests
different mechanisms, but the reason for this is still unknown. An
issue that strongly hampers the study of the biological mechanism
behind osteoinduction is the fact that a ceramics-induced hetero-
topic bone formation preferentially occurs in large animals, such
as baboons, dogs, sheep and goats and less so in rodents such as
mice and rats, as was shown in a number of studies comparing
osteoinductive potential of ceramics in different animal species
[219,245]. In a recent study by Barradas et al. in which 10 different
mouse strains were compared, only one was found to be suitable
for studying osteoinduction by biomaterials, suggesting the im-
portance of genetic make-up [231]. Finally, also the exact implan-
tation location (subcutaneous versus intramuscular) and size of the
implant were shown to affect the extent of new bone formation
[240].
Within the limitations described here, various attempts have
been made, on the one hand, to understand which material
properties are essential for rendering a ceramic osteoinductive,
and on the other hand, to describe biological mechanisms behind
the phenomenon of osteoinduction. Chemical composition, mac-
rostructure and surface micro- and nanostructural properties have
all been looked into for their relevance in the process of osteoin-
duction. Regarding the effect of chemical composition, as was
mentioned earlier, CaPs with different phase composition have
shown the ability to induce bone formation. A few studies com-
paring HA and TCP, or HA and BCP, have demonstrated that the
presence of a more soluble phase is beneficial for the amount of
induced bone [218,219,222], while in other studies, it was shown80that the addition of TCP negatively affected bone induction [236]
and that a relatively stable surface was needed for de novo bone
formation to occur [239]. Based on the current knowledge, it is
suggested that an increase in in vivo degradability of CaPs in
general is beneficial for osteoinduction, however, a relatively
stable surface is required to facilitate de novo bone formation. In
other words, a compromise needs to be reached between the level
of dissolution/reprecipitation events occurring on the material
surface and the rate of surface disintegration due to in vivo degra-
dation [236,240]. In general, the effect of chemical composition
can be dual; on one hand, increased calcium and/or inorganic
phosphate ion concentrations as a consequence of release from the
ceramic upon implantation can have a direct effect on the osteo-
genic differentiation of stem cells, as was recently demonstrated in
vitro [260,261] and in vivo [132]. On the other hand, the proposed
origin of bioactivity of all CaPs, that is the precipitation of biolog-
ical apatite on the material surface in vivo, presumably incorporat-
ing endogenous proteins is also considered as possible indirect
effect of materials chemistry [262].
The overall geometry of the implant, that is the presence of pores
or predefined geometries, such as concavities and channels, or their
formation post-implantation, has also been shown to be important
to facilitate osteoinduction [179,215,224,240]. It has been suggested
that these ‘protected’ spaces were needed to reach optimal condi-
tions (e.g. calcium and phosphate ion concentrations) to trigger the
process of osteoinduction [263]. Recently, Davison et al. demon-
strated that osteoinduction indeed occurs on a planar surface of
ceramics as well, that is in the absence of protective areas such as
pores [264], although in lower amounts than with the macroporous
counterparts [238]. This suggests that macrostructure is important
but not essential property in the process.
Finally, surface structural properties including microporosity,
grain size and therewith-related specific surface area have been
shown to play a determinant role in the process of osteoinduction
by biomaterials (Fig. 5). Concerning CaPs, important information
about the effect of surface structural properties stems from studies
in which sintering temperature was used as a tool to control grain
size and microporosity [234,238,239,241]. Based on these studies,
it was concluded that the submicrometer scale of grains and pores
on the surface is the property which renders a ceramic osteoin-
ductive [234]. This was specifically demonstrated for sintered
ceramics, and although this finding cannot be directly extrapolat-
ed to all CaPs, the importance of surface-structural features is
evident.
The identification of properties which influence a ceramic’s
ability to induce heterotopic bone formation (a more comprehen-
sive overview can be found elsewhere [263]), has resulted in
improvement of the existing and development of new biomater-
ials with intrinsic osteoinductivity, yet, no recipe exists for the
optimal osteoinductive materials. One of the important reasons is
that CaP materials are highly complex structures with intertwined
properties, making it difficult to change one without affecting the
others [265]. This explains why researchers have not succeeded yet
at pinpointing a property or combination of properties that is
essential for osteoinduction to occur. This is also true for the
biological cascade leading to de novo bone formation. A few
mechanisms have been proposed that are involved in this process,
but no conclusive evidence exists so far. For example, it is not
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FIGURE 5
Physicochemical properties of calcium phosphate ceramics influence their intrinsic osteoinductivity. Osteoinductive biphasic calcium phosphate ceramic with
small grains and micropores (a) induces bone formation upon 12-week intramuscular implantation in a goat (c), in contrast to its non-osteoinductive













wknown which cells in the heterotopic environment of muscle or
subcutis are the ones being triggered to differentiate into the
osteogenic lineage. Different theories exist in this regard, includ-
ing cells associated with microvessels, such as pericytes and
myoendothelial cells [218,235,245,246,266]. Using a canine mod-
el, Song et al. demonstrated that bone marrow stromal cells
migrate from bone marrow through blood circulation to the
heterotopic implantation site, possibly contributing to ceramic-
induced de novo bone formation [267]. Different theories have also
been proposed to explain the mechanism leading to bone forma-
tion. These include (i) direct trigger of osteogenic differentiation
through physicochemical properties described above [222], (ii)
trigger of osteogenic differentiation through accumulation or
local production of endogenous osteoinductive proteins such as
BMP-2 [215,253,268], (iii) osteogenic differentiation that is indi-
rectly triggered as a consequence of the inflammatory response
[269], and/or (iv) the process of osteoclastogenesis [233,234].
The mechanism governing osteoinduction by biomaterials can-
not be discussed without shedding light upon a frequently ob-served clinical problem that closely resembles osteoinduction:
heterotopic ossification. Heterotopic ossification, sometimes also
called pathological ossification, is often simply defined as the
presence of bone in soft tissue where bone normally does not
exist. Heterotopic ossification can roughly be divided into two
forms. The first, acquired form is often associated with trauma
(fracture, total hip arthroplasty, muscular trauma) or has a neuro-
genic cause (spinal cord or central nervous system injuries) and is
most common. In addition, there is the rare hereditary form,
including diseases such as fibrodisplasia ossificans progressiva, pro-
gressive osseous heteroplasia and Albright hereditary osteodistro-
phy [270]. In both forms of heterotopic ossification, trauma or
injury to the skeleton or soft tissue are the inducing events
[271,272]. While clearly during heterotopic implantation of a
material the surrounding tissue experiences injury, a material-
induced de novo bone formation cannot be defined as simply a
case of heterotopic ossification. As it was already mentioned, only
some synthetic biomaterials, with specific properties, possess
osteoinductive potential. Besides, a material-induced heterotopic81











eviewbone formation is always strongly associated to the implanted
material, and is never found in the soft tissue distant from the
material’s surface. This, however, does not mean that similar
biological mechanisms could not be involved in both phenomena.
It is probably a matter of time for the mechanisms behind
osteoinduction to be fully unraveled, and for instructions as of
how to produce a material with most pronounced or fastest
occurring osteoinductivity, to be written. To achieve this, it is
important to put efforts into separating individual properties of
functional materials from one another and investigating their
independent effects on biological response. Advantages for the
clinical setting that synthetic biomaterials with superior biological
performance, including intrinsic osteoinductivity and fast and
successful healing of challenging bone defects, offer over biologics,
justify these efforts.
One of the attractive approaches to enhance and accelerate
osteoinductivity  and bone defect healing capacity, while retain-
ing their synthetic character, is the use of the, so-called, bioi-
norganics. These are relatively simple compounds, often present
in the human body in trace amounts (e.g. in bone tissue) and yet
known to play an essential role in normal functioning of organs
and tissues. As extensively described in a recent review [273],
strontium ranelate [274–276], which is an anti-osteoporotic
agent, and fluoride [277,278], being an anti-cariogenic agent,
are two well-known examples of a clinical application of bioi-
norganics in orthopedics and dentistry. While strontium rane-
late is generally administered systemically, a growing need
exists for local delivery methods, for example at the location
of bone defects in the case of bone graft substitutes. Initially,
bioinorganics were used in conjunction with bone graft sub-
stitutes and other orthopedic, craniomaxillofacial and dental
implants with the aim to accelerate bone formation and improve
bone bonding. For example, a large amount of work on silicon-
substituted CaPs has been published since the 1990s [279–283].
But also strontium- [284–289], magnesium- [285–287], fluoride-
[290,291] and zinc- [288,292–294] incorporation into CaPs,
among other elements, as well as incorporation of combinations
of bioinorganics [288,292,295–297] have been extensively in-
vestigated in this context. As mentioned before, CaPs are known
to be capable of a large variety of anionic and cationic substitu-
tions, making them a relatively easy-to-produce delivery vehicle
for bioinorganics. Indeed, the incorporation of elements of
interest can be achieved by the addition of a precursor during
CaP powder precipitation, sol–gel process or in a solid-state
reaction, and a great number of ion-substituted synthetic bone
grafts exist, varying from bulk ceramics, cements and coatings
on metallic and polymeric substrates [298]. While it is relatively
easy to prepare bioinorganics-containing CaPs, the question
remains whether these structures are optimal carriers and deliv-
ery vehicles for bioinorganics. If it is difficult to describe which
property or properties are essential for a CaP ceramic to be
osteoinductive as was described earlier, the addition of another
ion into the CaP lattice will complicate this understanding even
further. An important reason for this is that ionic substitution
and, to a lesser extent, even physical entrapment of the com-
pound of interest inside the ceramic material, will affect its
physicochemical and biological properties. As an example, Ca
can be fully substituted by Sr in the HA crystals. However, this82results in a change of the surface morphology, with smaller and
less sharp crystals formed, due to a difference in the ionic
diameter between Ca2+ and Sr2+ [299,300]. Furthermore, stron-
tium-substituted HA is more soluble than the phase-pure ceram-
ic [301]. Finally, the release of Sr2+ is in principle dependent on
the degradation of the structural ceramic phase, meaning that
Sr2+ release is always accompanied by calcium and phosphate
release. In other words, even when we observe differences be-
tween the biological responses to a phase-pure and a substituted
ceramic, it is very difficult to conclude whether the difference is
a consequence of the bioinorganic release, or of the change to
the structural ceramic introduced by the addition of the com-
pound. Also here, these individual effects will have to be sepa-
rated to understand the mechanisms behind their action, which
in turn can be used as input for the development of improved or
completely new bone graft substitutes. This may require alter-
native approaches toward biomaterial development, where dif-
ferent materials and technologies are combined, instead of
relying on the processing parameters that often limit the free-
dom of design.
Outlook
So far, we have highlighted important recent developments in CaP
research, divided into topics of biomineralization, nanoparticles
for targeted delivery and bone graft substitution. In this last
section, we will touch upon a few topics, which we believe are
worth investing in to secure the place for CaPs in future biomedical
applications.
Identifying the relevant mineralization pathway
The results presented on biomineralization starting from the 2000s
have brought valuable insights, of which some are already imple-
mented in (preliminary) biomedical research [302]. In particular,
the fact that in most biomineralization systems an amorphous
phase is used as a precursor, indicates that this material could be
the material of choice for bone implants, especially in the case of
tissue-engineered constructs. ACP can be expected to be easily
resorbed and restructured in vivo, although additives like charged
molecules/proteins may be necessary to stabilize the material and
perhaps manipulate its crystallization pathway. The most chal-
lenging task in the future, however, will be to identify the miner-
alization processes relevant for human bone remodeling. As most
biomineralization studies are filled with short-cuts and artifacts
that hamper the correct interpretation of the data, in situ investi-
gation of bone formation and remodeling, such as recently per-
formed with zebrafish larvae [33,35], is hereby the most promising
pathway to follow.
Multifunctional nanoscopic CaP materials
CaP with nanoscale dimensions is well suited to interact with
(bio-)molecules of all kinds due to the polar surface. This,
together with the inherent non-toxicity and biodegradability
inside cells and the body has the potential of a cell- and tissue-
specific application, for example to fill bone defects (with ag-
glomerated nanoparticles) or to combat diseases or infections in
the body (with dispersed nanoparticles, for example in the
bloodstream). Multifunctional CaP nanoparticles which com-
bine drug delivery, imaging and targeting capabilities still have










wto be developed, but in general, they are more versatile than
metallic nanoparticles (with a solid core and an unknown degree
of biodegradability), polymeric nanoparticles which typically
consist of non-biological compounds, and liposomal or micellar
constructs that are ‘soft’ by nature without a solid core.
Load-bearing bone graft substitutes
Currently, bone graft substitutes have three important weak-
nesses: their handling properties, their insufficient osteoinduc-
tivity/bone regenerative potential, and their inability to provide
both cortical bone-like mechanical properties and excellent
biological properties. The first two topics were discussed in
length in this review. The last topic is an ‘old new’ topic. Indeed,
researchers already tried in the 1970s and 1980s to provide boneFIGURE 6
(a) Almost uniform b-TCP platelets with high aspect ratio and small thicknesses. 
engineering construct after 24 weeks of implantation showing vessel growth (gre
implanted scaffold (white); Image width: roughly 2 mm (Courtesy of V. Komlev an
micro-computed tomography (mCT) image. Scale bar: 1 mm. (a) Histological secti
stained in toluidine blue. Color code: gray/white: soft tissue, light blue: ceramic, d
obtained by comparing the mCT image of the b-TCP implant before and after im
code: blue: soft tissue; red = ceramic; gray = zones within the ceramic with a high
where the ceramic was resorbed during implantation; black: zones where the cer
(Courtesy of Courtesy of A. Sweedy and G. Baroud, Universite´ de Sherbrooke, Can
section shown in (c). Color code: white = high radio-density; black = low radio-degraft substitutes with mechanical properties of cortical bone,
but their efforts failed due to the intrinsic brittleness of ceramics,
the biocompatibility  issues caused by the use of large volumes of
degradable polymers or metals [303], and the difficulties to
combine polymers with ceramics without compromising the
mechanical properties [170,171]. Recent knowledge from the
field of biomineralization has clearly indicated that the archi-
tecture of natural composites such as bone and nacre is respon-
sible for their high tensile and toughness properties [304,305].
Also, various authors have proposed innovative methods to
produce architecturally complex structures with high level of
control and have shown that outstanding properties can be
achieved [306–310]. Finally, uniform CaP particles displaying
high aspect ratios, and sub-micrometric thicknesses can beScale bar: 2 mm. (b) 3D pseudo-holotomographic images of a tissue-
en) and newly-formed bone (brown/pink) in one single pore of the
d R. Cancedda) [319]; (c–e) direct comparison between histology and
on of a b-TCP scaffold after 6 weeks of implantation [402]. The section is
ark blue: ‘bone’. (d) mCT image of the histological section; the image is
plantation and extracting the histological section from the 3D image. Color
er radio-density than the ceramic in red; green = bone; yellow = zone
amic was resorbed during implantation and replaced by new bone

















eviewproduced [311–315] (Fig. 6a). This, taken together, should lead
to development of resorbable bone graft substitutes combining
high bioactivity and cortical bone-like tensile properties in the
near future.
Understanding and controlling the in vivo behavior of bone
graft substitutes
As underlined in the present manuscript, many aspects of the in vivo
behavior of bone graft substitutes are still poorly understood: What
is the exact mechanism behind osteoinductivity? What is the opti-
mal chemistry and optimal architecture of a bone graft substitute?
Answering these questions will lead to major advancements in
properties and performance of the existing bone graft substitutes.
To this end, both technological developments allowing a more
precise design and production of biomaterials with well-defined
properties and improved assays to study interactions of biomaterials
with a biological system will play an important role. For example, it
is envisioned that conventional techniques to produce bone graft
substitute will be replaced by those allowing design of scaffolds with
precise architectures to obtain new insights into the cell–material
interactions, such as the importance of surface curvature [316,317].
Another example includes the application of patterning techniques
of chemical or structural cues to obtain spatial and/or temporal
control over a biological response (Fig. 4d). Advancements in bio-
logical assays will, on the other hand, bring deeper understanding of
cell–material and tissue–material interactions. For example, the
availability of genomics data describing these interactions is grow-
ing [318]. Also advanced and/or multi-imaging approaches provide
unprecedented details about the healing process of soft and hard
tissues, not only post – but also during implantation [319–322]
(Fig. 6b–e). A particularly interesting novelty is the possibility to get
spatio-temporal information: how much resorption and bone for-
mation occurs in one specific pore over time? Is there a correlation
between these two phenomena [265,323]? It is envisioned that,
eventually, we will have information on correlation between a
specific property of a biomaterial and a specific biological response.
A next step will then be development of smart strategies to combine
right properties to obtain desired response. This approach will also
require the use of heavy and complex data processing tools, but for
some research groups, this is already reality.
CaPs as bioinorganics reservoirs
Increasing amount of evidence gathered over the past 15 years
demonstrates that the delivery of specific ions can trigger biological
responses. The next step in the bioinorganics research is to step away
from the idea of these ions being a structural component of CaPs as
substitute in CaP crystal lattice, like in natural bone, but to consider
them as drugs. This will require different strategies to control and
monitor their release and consequent biological response [324], like
in the case of classical drugs or growth factors. CaP could then be
reservoirs of calcium or phosphate ions, or other bioinorganics, but
polymers can also be used to locally deliver calcium or phosphate
[325]. In vitro screening methods to identify biological response to a
(combination of) bioinorganics is the first step in this direction
[326], but eventually, in situ ion release should be achieved and
coupled to an analysis of the in vivo response.84Conclusion
Here we have given an overview of some truly impressive advances
achieved in the past 15 years in the field of CaPs. Not only did the
knowledge of fundamental processes governing biomineralization
of CaPs grow tremendously, but their application as targeted
delivery vehicles and as synthetic bone graft substitutes has dem-
onstrated very important successes. Maybe because they have been
out there and clinically used for over 40 years now, these successes
have been somewhat downplayed among other developments in
the field of biomaterials. This, however, does not reflect the
enormous diversity CaPs have to offer both in terms of products
and their applications. And these have not yet been explored to
their maximum extent. Recent technological developments will
bring the CaP research and development another step further,
which fits well in the search for largely available and affordable
strategies for damaged and diseased bone in our aging population.
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